Morphic Holding Inc (MORF)
30.30
-0.52
(-1.69%)
USD |
NASDAQ |
May 31, 16:00
30.33
+0.03
(+0.10%)
After-Hours: 20:00
Morphic Cash from Operations (TTM): -127.25M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -127.25M |
| December 31, 2023 | -112.31M |
| September 30, 2023 | -108.86M |
| June 30, 2023 | -104.50M |
| March 31, 2023 | -104.28M |
| December 31, 2022 | -100.98M |
| September 30, 2022 | -96.44M |
| June 30, 2022 | -96.13M |
| March 31, 2022 | -91.22M |
| December 31, 2021 | -83.46M |
| September 30, 2021 | -77.29M |
| Date | Value |
|---|---|
| June 30, 2021 | -48.98M |
| March 31, 2021 | -47.44M |
| December 31, 2020 | -45.99M |
| September 30, 2020 | -45.65M |
| June 30, 2020 | -63.07M |
| March 31, 2020 | -60.78M |
| December 31, 2019 | -41.65M |
| September 30, 2019 | 64.98M |
| June 30, 2019 | 73.36M |
| March 31, 2019 | 81.95M |
| December 31, 2018 | 76.34M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-127.25M
Minimum
Mar 2024
73.36M
Maximum
Jun 2019
-65.90M
Average
-80.38M
Median
Cash from Operations (TTM) Benchmarks
| Alnylam Pharmaceuticals Inc | 189.12M |
| Cytokinetics Inc | -421.55M |
| Amicus Therapeutics Inc | -80.72M |
| Insmed Inc | -573.98M |
| Madrigal Pharmaceuticals Inc | -389.32M |